SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Fundamental Analysis & Valuation

FRA:1SXP • DE000A3ENQ51

Current stock price

13.7 EUR
+0.08 (+0.59%)
Last:

This 1SXP.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. 1SXP.DE Profitability Analysis

1.1 Basic Checks

  • 1SXP had positive earnings in the past year.
  • 1SXP had a positive operating cash flow in the past year.
  • Each year in the past 5 years 1SXP has been profitable.
  • In the past 5 years 1SXP always reported a positive cash flow from operatings.
1SXP.DE Yearly Net Income VS EBIT VS OCF VS FCF1SXP.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 9.26%, 1SXP belongs to the top of the industry, outperforming 80.95% of the companies in the same industry.
  • 1SXP's Return On Equity of 16.21% is amongst the best of the industry. 1SXP outperforms 85.71% of its industry peers.
  • 1SXP has a better Return On Invested Capital (12.84%) than 85.71% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for 1SXP is in line with the industry average of 13.93%.
Industry RankSector Rank
ROA 9.26%
ROE 16.21%
ROIC 12.84%
ROA(3y)10.63%
ROA(5y)11.2%
ROE(3y)19.15%
ROE(5y)19.86%
ROIC(3y)14.59%
ROIC(5y)15.53%
1SXP.DE Yearly ROA, ROE, ROIC1SXP.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 5 10 15 20

1.3 Margins

  • 1SXP has a Profit Margin of 15.13%. This is in the better half of the industry: 1SXP outperforms 76.19% of its industry peers.
  • 1SXP's Profit Margin has improved in the last couple of years.
  • 1SXP has a better Operating Margin (19.08%) than 76.19% of its industry peers.
  • 1SXP's Operating Margin has improved in the last couple of years.
  • With a Gross Margin value of 33.68%, 1SXP perfoms like the industry average, outperforming 42.86% of the companies in the same industry.
  • 1SXP's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 19.08%
PM (TTM) 15.13%
GM 33.68%
OM growth 3Y-2.54%
OM growth 5Y4%
PM growth 3Y-0.93%
PM growth 5Y2.28%
GM growth 3Y-2.25%
GM growth 5Y0.1%
1SXP.DE Yearly Profit, Operating, Gross Margins1SXP.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. 1SXP.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so 1SXP is still creating some value.
  • The number of shares outstanding for 1SXP remains at a similar level compared to 1 year ago.
  • 1SXP has about the same amout of shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, 1SXP has an improved debt to assets ratio.
1SXP.DE Yearly Shares Outstanding1SXP.DE Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 50M 100M 150M
1SXP.DE Yearly Total Debt VS Total Assets1SXP.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • 1SXP has a debt to FCF ratio of 7.05. This is a slightly negative value and a sign of low solvency as 1SXP would need 7.05 years to pay back of all of its debts.
  • 1SXP has a Debt to FCF ratio of 7.05. This is in the better half of the industry: 1SXP outperforms 61.90% of its industry peers.
  • A Debt/Equity ratio of 0.08 indicates that 1SXP is not too dependend on debt financing.
  • The Debt to Equity ratio of 1SXP (0.08) is better than 90.48% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 7.05
Altman-Z N/A
ROIC/WACC1.45
WACC8.84%
1SXP.DE Yearly LT Debt VS Equity VS FCF1SXP.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 1.58 indicates that 1SXP should not have too much problems paying its short term obligations.
  • 1SXP's Current ratio of 1.58 is in line compared to the rest of the industry. 1SXP outperforms 57.14% of its industry peers.
  • 1SXP has a Quick Ratio of 1.17. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.17, 1SXP is in the better half of the industry, outperforming 61.90% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.58
Quick Ratio 1.17
1SXP.DE Yearly Current Assets VS Current Liabilites1SXP.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. 1SXP.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 12.36% over the past year.
  • The Earnings Per Share has been growing by 13.78% on average over the past years. This is quite good.
  • The Revenue has been growing slightly by 4.39% in the past year.
  • The Revenue has been growing by 11.04% on average over the past years. This is quite good.
EPS 1Y (TTM)12.36%
EPS 3Y5.42%
EPS 5Y13.78%
EPS Q2Q%15.79%
Revenue 1Y (TTM)4.39%
Revenue growth 3Y6.3%
Revenue growth 5Y11.04%
Sales Q2Q%4.5%

3.2 Future

  • Based on estimates for the next years, 1SXP will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.01% on average per year.
  • 1SXP is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.75% yearly.
EPS Next Y-1.71%
EPS Next 2Y6.04%
EPS Next 3Y8.07%
EPS Next 5Y8.01%
Revenue Next Year2.29%
Revenue Next 2Y4.62%
Revenue Next 3Y5.35%
Revenue Next 5Y5.75%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
1SXP.DE Yearly Revenue VS Estimates1SXP.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
1SXP.DE Yearly EPS VS Estimates1SXP.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1

More info and screens

Find the best growth stocksShow best growing peers

5

4. 1SXP.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 13.70, the valuation of 1SXP can be described as correct.
  • Based on the Price/Earnings ratio, 1SXP is valued cheaply inside the industry as 90.48% of the companies are valued more expensively.
  • 1SXP's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.17.
  • The Price/Forward Earnings ratio is 12.56, which indicates a correct valuation of 1SXP.
  • 90.48% of the companies in the same industry are more expensive than 1SXP, based on the Price/Forward Earnings ratio.
  • 1SXP's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.05.
Industry RankSector Rank
PE 13.7
Fwd PE 12.56
1SXP.DE Price Earnings VS Forward Price Earnings1SXP.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 1SXP indicates a rather cheap valuation: 1SXP is cheaper than 90.48% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, 1SXP is valued a bit more expensive than the industry average as 61.90% of the companies are valued more cheaply.
Industry RankSector Rank
P/FCF 173.73
EV/EBITDA 7.73
1SXP.DE Per share data1SXP.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • 1SXP has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.99
EPS Next 2Y6.04%
EPS Next 3Y8.07%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. 1SXP.DE Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 1.33%, 1SXP has a reasonable but not impressive dividend return.
  • 1SXP's Dividend Yield is rather good when compared to the industry average which is at 0.45. 1SXP pays more dividend than 95.24% of the companies in the same industry.
  • 1SXP's Dividend Yield is slightly below the S&P500 average, which is at 1.89.
Industry RankSector Rank
Dividend Yield 1.33%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years2
Div Non Decr Years2
1SXP.DE Yearly Dividends per share1SXP.DE Yearly Dividends per shareYearly Dividends per share 2024 2025 2026 0.05 0.1 0.15

5.3 Sustainability

  • 15.99% of the earnings are spent on dividend by 1SXP. This is a low number and sustainable payout ratio.
DP15.99%
EPS Next 2Y6.04%
EPS Next 3Y8.07%
1SXP.DE Yearly Income VS Free CF VS Dividend1SXP.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2020 2021 2022 2023 2024 2025 50M 100M 150M
1SXP.DE Dividend Payout.1SXP.DE Dividend Payout, showing the Payout Ratio.1SXP.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

1SXP.DE Fundamentals: All Metrics, Ratios and Statistics

SCHOTT PHARMA AG& CO KGAA

FRA:1SXP (4/2/2026, 7:00:00 PM)

13.7

+0.08 (+0.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-11
Earnings (Next)05-13
Inst Owners20.95%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.06B
Revenue(TTM)996.56M
Net Income(TTM)150.74M
Analysts76.84
Price Target19.93 (45.47%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.33%
Yearly Dividend0.16
Dividend Growth(5Y)N/A
DP15.99%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.69%
Min EPS beat(2)-3.5%
Max EPS beat(2)14.88%
EPS beat(4)2
Avg EPS beat(4)3.95%
Min EPS beat(4)-3.5%
Max EPS beat(4)14.88%
EPS beat(8)3
Avg EPS beat(8)2.57%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.32%
Min Revenue beat(2)-1.99%
Max Revenue beat(2)2.64%
Revenue beat(4)2
Avg Revenue beat(4)0.03%
Min Revenue beat(4)-2.27%
Max Revenue beat(4)2.64%
Revenue beat(8)3
Avg Revenue beat(8)0.09%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-16.6%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9.81%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.05%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.87%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.81%
Valuation
Industry RankSector Rank
PE 13.7
Fwd PE 12.56
P/S 2.07
P/FCF 173.73
P/OCF 12.98
P/B 2.22
P/tB 2.29
EV/EBITDA 7.73
EPS(TTM)1
EY7.3%
EPS(NY)1.09
Fwd EY7.96%
FCF(TTM)0.08
FCFY0.58%
OCF(TTM)1.06
OCFY7.7%
SpS6.62
BVpS6.18
TBVpS5.98
PEG (NY)N/A
PEG (5Y)0.99
Graham Number11.79
Profitability
Industry RankSector Rank
ROA 9.26%
ROE 16.21%
ROCE 16.05%
ROIC 12.84%
ROICexc 13.2%
ROICexgc 13.55%
OM 19.08%
PM (TTM) 15.13%
GM 33.68%
FCFM 1.19%
ROA(3y)10.63%
ROA(5y)11.2%
ROE(3y)19.15%
ROE(5y)19.86%
ROIC(3y)14.59%
ROIC(5y)15.53%
ROICexc(3y)15.01%
ROICexc(5y)16.12%
ROICexgc(3y)15.5%
ROICexgc(5y)16.82%
ROCE(3y)18.26%
ROCE(5y)19.44%
ROICexgc growth 3Y-6.05%
ROICexgc growth 5Y-8.67%
ROICexc growth 3Y-5.65%
ROICexc growth 5Y-7.55%
OM growth 3Y-2.54%
OM growth 5Y4%
PM growth 3Y-0.93%
PM growth 5Y2.28%
GM growth 3Y-2.25%
GM growth 5Y0.1%
F-Score7
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 7.05
Debt/EBITDA 0.29
Cap/Depr 178.66%
Cap/Sales 14.76%
Interest Coverage 13.03
Cash Conversion 58.33%
Profit Quality 7.88%
Current Ratio 1.58
Quick Ratio 1.17
Altman-Z N/A
F-Score7
WACC8.84%
ROIC/WACC1.45
Cap/Depr(3y)260.7%
Cap/Depr(5y)265.72%
Cap/Sales(3y)16.46%
Cap/Sales(5y)16.64%
Profit Quality(3y)27.05%
Profit Quality(5y)27.58%
High Growth Momentum
Growth
EPS 1Y (TTM)12.36%
EPS 3Y5.42%
EPS 5Y13.78%
EPS Q2Q%15.79%
EPS Next Y-1.71%
EPS Next 2Y6.04%
EPS Next 3Y8.07%
EPS Next 5Y8.01%
Revenue 1Y (TTM)4.39%
Revenue growth 3Y6.3%
Revenue growth 5Y11.04%
Sales Q2Q%4.5%
Revenue Next Year2.29%
Revenue Next 2Y4.62%
Revenue Next 3Y5.35%
Revenue Next 5Y5.75%
EBIT growth 1Y18.83%
EBIT growth 3Y3.6%
EBIT growth 5Y15.48%
EBIT Next Year36.02%
EBIT Next 3Y18.01%
EBIT Next 5Y13.81%
FCF growth 1Y-55.75%
FCF growth 3Y6.15%
FCF growth 5Y12.98%
OCF growth 1Y-19.95%
OCF growth 3Y-0.4%
OCF growth 5Y11.5%

SCHOTT PHARMA AG& CO KGAA / 1SXP.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for SCHOTT PHARMA AG& CO KGAA?

ChartMill assigns a fundamental rating of 6 / 10 to 1SXP.DE.


What is the valuation status for 1SXP stock?

ChartMill assigns a valuation rating of 5 / 10 to SCHOTT PHARMA AG& CO KGAA (1SXP.DE). This can be considered as Fairly Valued.


Can you provide the profitability details for SCHOTT PHARMA AG& CO KGAA?

SCHOTT PHARMA AG& CO KGAA (1SXP.DE) has a profitability rating of 7 / 10.


What is the earnings growth outlook for SCHOTT PHARMA AG& CO KGAA?

The Earnings per Share (EPS) of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is expected to decline by -1.71% in the next year.


Is the dividend of SCHOTT PHARMA AG& CO KGAA sustainable?

The dividend rating of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 4 / 10 and the dividend payout ratio is 15.99%.